We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 140% below its sector, cheaper than its peers on earnings.
ToolGen Incorporated is a biotechnology enterprise based in South Korea, primarily focused on pioneering advancements in genome editing technology. The company's main endeavor involves engineering CRISPR-Cas9 genetic modification tools specifically designed for editing genes in eukaryotic cells. Furthermore, its operations extend to commercializing its intellectual property, exploring therapeutic applications, and participating in the seed sector. Established in 1999, ToolGen's corporate headquarters are situated in Seoul, South Korea.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 199800.KQ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
